NanoViricides, a clinical-stage pharmaceutical company specializing in host-mimetic nanomedicine technology, is scheduled to present at the D. Boral Capital Inaugural Global Conference in New York City. Anil R. Diwan, the company's President and Executive Chairman, will host investor meetings, providing insights into the company's innovative antiviral drug development strategy.
The company's lead drug candidate, NV-387, represents a significant advancement in broad-spectrum antiviral treatments. Designed to potentially address respiratory viral infections including RSV, COVID-19, Long COVID, influenza, and MPOX/Smallpox, NV-387 demonstrates the company's commitment to developing versatile therapeutic solutions.
NanoViricides is currently focused on advancing NV-387 into Phase II human clinical trials, signaling a critical stage in the drug's development process. Additionally, the company is developing NV-HHV-1 for treating Shingles, further expanding its therapeutic portfolio.
The conference presentation offers investors and industry professionals an opportunity to understand NanoViricides' innovative approach to antiviral drug development. By leveraging proprietary nanomaterial technologies licensed from TheraCour Pharma, Inc., the company is positioning itself at the forefront of potential breakthrough treatments for complex viral infections.
